Plus Therapeutics reports 2024 net loss of $13.0M, cash $3.6M; raised $15M in private placement

PLUS THERAPEUTICS, INC.

Cash and investments $3.6M at Dec 31, 2024 vs $8.6M at Dec 31, 2023.
Net loss $13.0M ($1.95 per share) in 2024 vs $13.3M ($4.24 per share) in 2023; operating loss $14.7M.
Raised $15.0M via private placement, regains Nasdaq compliance and extends runway into 2026.
FDA agreed on brand name REYOBIQ; orphan drug designation for leptomeningeal metastases in lung cancer.
Appointed Dr. Michael Rosol as Chief Development Officer; Russell Bradley as President/GM of CNSide Diagnostics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.